Tardive dyskinesia in the elderly: Data from a prospective study

Psychiatric Annals

Volumn 32, Issue 4, 2002, Pages

  Kane, John M ^a  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; CHLORPROMAZINE; HALOPERIDOL; INSULIN; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

CONFIDENCE INTERVAL; DIABETES MELLITUS; DOSE RESPONSE; DRUG EXPOSURE; EDENTULOUSNESS; ELECTROCONVULSIVE THERAPY; EXTRAPYRAMIDAL SYMPTOM; GENDER; GERIATRIC PATIENT; HUMAN; INCIDENCE; INVOLUNTARY MOVEMENT; LONG TERM CARE; MENTAL DISEASE; MOOD DISORDER; NEUROLOGIC DISEASE; PREVALENCE; PROSPECTIVE STUDY; REVIEW; RISK FACTOR; SIDE EFFECT; TARDIVE DYSKINESIA;

EID: 0242382828     PISSN: 00485713     EISSN: None     Source Type: Journal    
DOI: 10.3928/0048-5713-20020401-07     Document Type: Review

References (16)

1. Kane JM, Jeste DV, Barnes TRE, et al. American Psychiatric Association Task Force Report on Tardive Dyskinesia. Washington, DC: American Psychiatric Press; 1992.
2. Kane JM. Tardive dyskinesia: epidemiological and clinical presentation. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1995:1485-1495.
3. Kane JM, Smith J. Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry. 1982;39:473-481.
4. Smith JM, Baldessarini RJ. Changes in prevalence, severity, and recovery in tardive dyskinesia with age. Arch Gen Psychiatry. 1980;37:1368-1371.
5. Woerner MG, Kane JM, Lieberman JA, et al. The prevalence of tardive dyskinesia. J Clin Psychopharmacol. 1991;11:34-42.
6. Kane JM, Woerner M, Lieberman J. Tardive dyskinesia: prevalence, incidence, and risk factors. J Clin Psychopharmacol. 1988;8(suppl 4):52S-56S.
7. Morgenstern H, Glazer W. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study. Arch Gen Psychiatry. 1993;50:723-733.
8. Glazer WM. Review of incidence studies of tardive dyskinesia associated with typical antipsychotics. J Clin Psychiatry. 2000;61(suppl 4):15-20.
9. Woerner MG, Alvir JM, Saltz BL, Lieberman JA, Kane JM. Prospective study of tardive dyskinesia in the elderly: rates and risk factors. Am J Psychiatry. 1998;155:1521-1528.
10. Simpson GM, Lee JH, Zoubok B, Gardos G. A rating scale for tardive dyskinesia. Psychopharmacology (Berl). 1979;64:171-179.
11. Yassa R, Nastase C, Dupont D, Thibeau M. Tardive dyskinesia in elderly psychiatric patients: a 5-year study. Am J Psychiatry. 1992;149:1206-1211.
12. Jeste DV, Caligiuri MP, Paulsen JS, et al. Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients. Arch Gen Psychiatry. 1995;52:756-765.
13. Kane JM, Woerner M, Safferman A, Pollack S, Lieberman J. Does clozapine cause tardive dyskinesia? J Clin Psychiatry. 1993;54:327-330.
14. Tollefson GD, Beasley CM Jr, Tamura RN, Tran PV, Potvin JH. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry. 1997;154:1248-1254.
15. Jeste DV, Okamoto A, Napolitano J, Kane JM, Martinez RA. Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am J Psychiatry. 2000;157:1150-1155.
16. Tariot P, Salzman C, Yeung P, et al. Clinical improvement and tolerability is maintained long term in elderly patients with psychotic disorder treated with Seroquel (quetiapine). Presented at: 152nd Annual Meeting of the American Psychiatric Association; May 15-20, 1999; Washington, DC.